Patent intelligence · US
US 11286264
Macrocyclic compounds and uses thereof
Macrocyclic compounds and uses thereof
Patent details — US 11286264
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 29, 2022
- Expiration
- Mar 24, 2042
- Applicant
- TURNING POINT THERAPEUTICS, INC.
- Claims
- 21
- CPC classes
- A61K, A61K45/06, A61P, A61P35/00
Quick answer
US 11286264 (Macrocyclic compounds and uses thereof) is held by TURNING POINT THERAPEUTICS, INC.. Status: granted. Granted Mar 29, 2022. Expires Mar 24, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TURNING POINT THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K45/06, A61P, A61P35/00
More from TURNING POINT THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12310968
Chiral diaryl macrocycles and uses thereof
granted -
US 12252488
HPK1 antagonists and uses thereof
granted -
US 12215105
HPK1 antagonists and uses thereof
granted -
US 12187739
Diaryl macrocycle polymorph
granted -
US 12071442
Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
granted -
US 11981684
Macrocyclic compounds and uses thereof
granted -
US 11926625
HPK1 antagonists and uses thereof
granted -
US 11802292
Modified orthopoxvirus vectors
granted
Related coverage
Frequently asked questions
What is US patent 11286264?
US 11286264 (Macrocyclic compounds and uses thereof) is held by TURNING POINT THERAPEUTICS, INC.. Status: granted. Granted Mar 29, 2022. Expires Mar 24, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11286264?
TURNING POINT THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 40 pharmaceutical patents for this assignee.
When does US 11286264 expire?
Our index shows an expiration date of Mar 24, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.